Androgen deprivation therapy (ADT) has evolved over the years, with recent research focused on GnRH antagonists. These findings seem to indicate that GnRH antagonists, namely degarelix, have better outcomes for cardiovascular morbidity, urinary tract infection rates, and onset of time of PSA progression versus other forms of ADT, according to Neal D. Shore, MD, FACS.
